Harith Rajagopalan, M.D., Ph.D., is Co-founder and CEO of Fractyl, having started the company while serving as an Entrepreneur-in-Residence at General Catalyst Partners in Cambridge, MA.

Prior to founding Fractyl, Harith was an academic cardiologist and physician-scientist. He received his B.S. in Chemistry from Stanford University, where he was elected to the Phi Beta Kappa academic honor society in his junior year which is reserved for students in the top 2% of their class. 

He went on to obtain M.D. and Ph.D. degrees from Johns Hopkins School of Medicine through the Medical Scientist Training Program (MSTP). At Johns Hopkins, Harith did groundbreaking and award-winning research on intestinal cancers that was published in top medical journals, including Nature and Science. Harith helped to establish BRAF as an important target for cancer drug development and received the prestigious Michael A. Shanoff Research Award for his doctoral thesis. He was also elected to the Alpha Omega Alpha medical society for scholarly achievement in medical school.

After medical school, Harith completed his medical training in Internal Medicine and Cardiovascular Medicine, both at Brigham and Women’s Hospital in Boston, and a research fellowship at the Harvard Stem Cell Institute at Harvard Medical School, before joining General Catalyst and co-founding Fractyl.